Home Cart 0 Sign in  

[ CAS No. 17641-08-6 ] {[proInfo.proName]}

,{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]}
Chemical Structure| 17641-08-6
Chemical Structure| 17641-08-6
Structure of 17641-08-6 * Storage: {[proInfo.prStorage]}

Please Login or Create an Account to: See VIP prices and availability

Cart0 Add to My Favorites Add to My Favorites Bulk Inquiry Inquiry Add To Cart

Search after Editing

* Storage: {[proInfo.prStorage]}

* Shipping: {[proInfo.prShipping]}

Quality Control of [ 17641-08-6 ]

Related Doc. of [ 17641-08-6 ]

Alternatived Products of [ 17641-08-6 ]
Product Citations

Product Details of [ 17641-08-6 ]

CAS No. :17641-08-6 MDL No. :MFCD00018900
Formula : C9H10ClNO2 Boiling Point : -
Linear Structure Formula :- InChI Key :JJNAIBJFYFWTIA-UHFFFAOYSA-N
M.W : 199.63 Pubchem ID :28667
Synonyms :

Calculated chemistry of [ 17641-08-6 ]      Expand+

Physicochemical Properties

Num. heavy atoms : 13
Num. arom. heavy atoms : 6
Fraction Csp3 : 0.22
Num. rotatable bonds : 4
Num. H-bond acceptors : 2.0
Num. H-bond donors : 1.0
Molar Refractivity : 52.04
TPSA : 38.33 Ų

Pharmacokinetics

GI absorption : High
BBB permeant : Yes
P-gp substrate : No
CYP1A2 inhibitor : Yes
CYP2C19 inhibitor : No
CYP2C9 inhibitor : No
CYP2D6 inhibitor : No
CYP3A4 inhibitor : No
Log Kp (skin permeation) : -6.15 cm/s

Lipophilicity

Log Po/w (iLOGP) : 1.64
Log Po/w (XLOGP3) : 1.92
Log Po/w (WLOGP) : 1.68
Log Po/w (MLOGP) : 1.54
Log Po/w (SILICOS-IT) : 1.9
Consensus Log Po/w : 1.74

Druglikeness

Lipinski : 0.0
Ghose : None
Veber : 0.0
Egan : 0.0
Muegge : 1.0
Bioavailability Score : 0.55

Water Solubility

Log S (ESOL) : -2.36
Solubility : 0.862 mg/ml ; 0.00432 mol/l
Class : Soluble
Log S (Ali) : -2.35
Solubility : 0.895 mg/ml ; 0.00448 mol/l
Class : Soluble
Log S (SILICOS-IT) : -3.55
Solubility : 0.0561 mg/ml ; 0.000281 mol/l
Class : Soluble

Medicinal Chemistry

PAINS : 0.0 alert
Brenk : 1.0 alert
Leadlikeness : 1.0
Synthetic accessibility : 1.53

Safety of [ 17641-08-6 ]

Signal Word:Warning Class:N/A
Precautionary Statements:P264-P270-P301+P312-P330-P501 UN#:N/A
Hazard Statements:H302 Packing Group:N/A
GHS Pictogram:

Application In Synthesis of [ 17641-08-6 ]

* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.

  • Downstream synthetic route of [ 17641-08-6 ]

[ 17641-08-6 ] Synthesis Path-Downstream   1~22

  • 2
  • [ 536-90-3 ]
  • [ 79-04-9 ]
  • [ 17641-08-6 ]
YieldReaction ConditionsOperation in experiment
91.5% With N-ethyl-N,N-diisopropylamine; In acetonitrile; at 20℃; for 1h;Inert atmosphere; To a solution of compound A (0.5 g, 4.05 mmoles) in ACN (10.0 mL) was added DIPEA (1.56 mL, 8.93 mmoles) , followed by dropwise addition of compound B (0.387 mL, 4.87 mmoles) under argon atmosphere. After the addition was complete the reaction was stirred at rt for 1 hour. The completion of the reaction was monitored by TLC. The reactionmixture was concentrated, purified by column chromatography (20 %EtOAc:Hexanes) to isolate the required compound as brown solid (0.74 g, 91.5%). 1H NMR (CDCl3, 400 MHz) δ 8.30 ( s, 1 H),7.28-7.23(m, 2 H), 7.03 (d, J=7.6 Hz, 1 H), 6.74-6.70(m, 1 H), 4.18 (s, 2 H), 3.81 (s, 3 H).
80.7% With pyridine; In dichloromethane; at 0 - 20℃; for 12h; Example 34 IV-1 6-(4-(4-(3-(6-fluoro-benzisoxazolyl))-1-piperidinyl)-n-butoxy)-indoline-2-one 1) 2 ml of pyridine is added to 30 ml of a solution of 3-methoxyaniline (4.92g, 40 mmol) in dichloromethane and the mixture is stirred for 5 minutes, while maintaining the temperature inside vessel at lower than 0C, and thereto 20 ml of a solution of chloroacetyl chloride (6.78g, 60 mmol) in dichloromethane is drop-added slowly. A reaction is carried out at room temperature for 12 hours after completion of drop-addition, and then terminated. The reaction solution is washed with 5% of HCl (30ml×3), 5% of NaOH (30ml×3), water (30ml×3), and saturated saline (30 ml) successively, dried over anhydrous magnesium sulfate and filtered. The filtrate is evaporated to remove the solvent to obtain 6.43g of 2-chloro-N-(3-methoxyphenyl)acetamide , with a yield of 80.7%.
80.7% With pyridine; In dichloromethane; at 0 - 20℃; for 12h; 2 ml of pyridine was added to 30 ml of a dichloromethane solution of 3-methoxyaniline (4.92 g, 40 mmol), and the mixture was stirred for 5 minutes. While maintaining the internal temperature at 0 C, a solution of chloroacetyl chloride (6.78 g, 60 mmol) in dichloromethane After completion of the dropwise addition, the reaction was stopped and the reaction solution was successively washed with 5% HCl 30 ml * 3, 5% NaOH 30 ml * 3, water 30 ml * 3, saturated Washed with 30 ml of brine, dried over anhydrous magnesium sulfate, filtered, the solvent was distilled off from the filtrate,6.43 g of 2-chloro-N-(3-methoxyphenyl)acetamide are obtained. Yield is 80.7%.
75.2% With potassium carbonate; In N,N-dimethyl-formamide; at 0 - 20℃; for 0.333333h; General procedure: In a round bottom flask, 10mmol aniline derivitives (4a-n) and 20mmol potassium carbonate were suspended in 15mL DMF and cooled to 0C. Then 12mmol chloroacethylchloride was added. The reaction mixture was then stirred at room temperature for 20min; quenched with saturated sodium hydrogen carbonate (10mL) and washed with water. The organic layer was separated and dried over sodium sulfate. The organic layer was evaporated under reduced pressure, and the crude reaction mixture was purified by column chromatography using chloroform and methanol as a mobile phase to obtain a pure compound [36-39]. The CAS-numbers and yield of synthesized compounds were reported in the supplementary file (Table S1).
75.8% With triethylamine; In dichloromethane; at 0℃; for 4h; General procedure: Weigh 0.51g (5mmol) of aniline (5mmol) and triethylamine in a 50mL round bottom flask, add 10mL of dichloromethane, use nitrogen protection, add 0.56g (5mmol) of chloroacetyl chloride, and place in an ice-water bath at 0 and stir. After reacting for 4 hours, add 20mL of dichloromethane to dilute the reaction, wash with 1M hydrochloric acid, saturated sodium bicarbonate solution and brine successively, and use rotary evaporation to remove dichloromethane to obtain substituted aniline (7)
70% General procedure: To a solution of substituted aniline (compounds 1a-1t) or 5-aminoindole and 6-aminoquinoline (1.0 equiv.) in dichloromethane (CH2Cl2) (15mL) at 0C, potassium carbonate (K2CO3) (2.0 equiv.) was added. The reaction was stirred at 0C for 15min. Into this stirring solution, chloroacetyl chloride (1.0 equiv.) was added dropwise at 0C. The mixture was stirred for 2hat room temperature. After completion of the reaction, water (20mL) was added, and the mixture was extracted with dichloromethane. The organic solvent phase was concentrated under vacuum to afford the desired compounds 2a-2t, 5a and 5b.
53.01% General procedure: Step 1. To the stirred solution of Aniline (1.0 equiv) in acetone was added K2CO3 (1.2 equiv.) at RT and stirred for 30min. Chloroacetyl chloride/substituted acetylchloride (1.1 equiv.) was then added at 0C and stirred for additional 3h at room temperature. After completion of the reaction (monitored by TLC), volatiles were removed on rotary evaporator and ethyl acetate was added. Organic layer were washed with water, aq NaHCO3, brine. Organic layer was dried over sodium sulfate and evaporated on rotary evaporator and the crude residue was purified by flash chromatography to give the desired product.
With pyridine; In water; at 0℃; for 1h; General procedure: Generalprocedure: To a solution of aniline or benzylamine (10 mmol) inwater (20 ml) and pyridine (1.6 ml) was added chloracetyl chloride(1.69 g, 15 mmol) slowly at 0 C. The reaction mixture was stirredat 0 C for 1.0 h and then diluted with water (50 ml). The precipitatewas collected by filtration, washed with water and dried undervacuum. N-substituted-2-chloroacetamides 3a-3r were obtainedas solid (yield 50-80%).
In N,N-dimethyl-formamide; at 20℃; for 0.333333h; General procedure: To a stirred solution of substituted aniline (1 mmol) and chloroacetyl chloride (1 mmol) which was stirred in 5 mL DMF for 20 min, were added benzyl amine derivatives (1.3 mmol) and CS2 (5 mmol). The reaction mixture was allowed to stir for required additional time (Table 2). Then, 5 mL of water was added and the solution was extracted with ethyl acetate and dried over sodium sulfate and purified by passing over a silica gel column chromatography using petroleum ether/ethyl acetate (8:2).
With triethylamine; In dichloromethane; at 20℃; for 0.5h; General procedure: To a solution of the appropriate amine (50 mmol) in triethylamine (5.1 mg, 50.5 mmol) and dichloromethane (50 mL), chloroacetyl chloride (70 mmol) was added dropwise, and the mixture was allowed to stir at room temperature for 30 min. Then, it was slowly poured into a saturated solution of NaHCO3 (100 mL). The layers were separated, and the aqueous layer was extracted with CH2-Cl2 (30 mL). The combined organic layers were dried over MgSO4, filtered, and concentrated under vacuum. The product was dried and recrystallized from ethyl acetate andpetroleum ether to obtain 2-chloro-N-substituted acetamides. The properties and analytical data for these compounds 15a-v were listed in the supporting information.
General procedure: Under nitrogen atmosphere, dry CH2Cl2 (30 mL), amine (0.02 mol), and Et3N (0.05 mol) wereadded to a three-necked round bottom ask and stirred for 0.5 h, then chloroacetyl chloride droppedslowly and reacted for 3 h at room temperature. Then, the solution was washed with 2 mol L1hydrochloric acid (30 mL), saturated aq NaHCO3 solution (30 mL), and brine (40 mL), successively,then dried over anhydrous Na2SO4 and filtered. After evaporating CH2Cl2 in vacuum, the obtainedcrude product was rened by recrystallization using ethyl acetate/petroleum ether.
In N,N-dimethyl-formamide; at 20℃; for 0.5h; General procedure: Mixture of amines 6 and chloroacetyl chloride 7 in DMF werestirred at room temperature for 30 min. At the end of the reaction(checked by TLC), the reaction mixture was diluted with water, pouredinto ice, and the obtained white precipitate was filtered off. The residuewas washed with water to obtain pure N-phenyl (or benzyl)-2-chloroacetamide8.
With triethylamine; In dichloromethane; at 0 - 25℃; for 20h; General procedure: 2-Chloroacetyl chloride (24 mmol) wasslowly added dropwise to a mixture of various anilines(20 mmol) and Et3N (24 mmol) in anhydrous CH2Cl2(20 mL) at 0 C. The reaction mixture was warmed to roomtemperature and stirred for an additional 20 h. After the solventwas removed under reduced pressure, the residue waswashed with ice water, and the precipitate was separatedby filtration. The crude product was purified by crystallizationusing a mixture of ether/hexane (2a-r).
In acetic acid; at 0 - 20℃; General procedure: Various substituted anilines were dissolved in glacial acetic acidat 0 C, to this was added over 30 min choloroacetylchloride (2equivalents). The reaction mixture was brought to room temperatureand stirred overnight. Saturated sodium bicarbonate solutionwas added till complete neutralization. The resulting precipitatewas filtered off and washed with n-hexane and dried. The resultantproduct was used further without any purification. Either of 3-hydroxy benzaldehyde, 4-hydroxy benzaldehyde, vanillin or isovanillin(1 equivalent) was dissolved in acetone and potassiumcarbonate (2 equivalents) was added. Then correspondingsubstituted acetamide was mixed to the stirring solution. Finally,potassium iodide (1.5 equivalent) was added. The reaction mixturewas refluxed for 8-10 h. After completion of reaction, the resultantmixture was concentrated and treated with water and extractedwith ethyl acetate (3 x 20 mL). The organic layers were combinedand treated with brine and dried over sodium sulfate andconcentrated. The crude mixture was purified over silica gel(60-120) using petroleum ether: ethyl acetate (9:1).
With acetic acid; at 0 - 20℃; General procedure: Various substituted anilines were dissolved in glacial acetic acid at0 C, to this was added over 30 min choloroacetyl chloride (2 equivalents).The reaction mixture was brought to room temperature andstirred overnight. Saturated sodium bicarbonate solution was added tillcomplete neutralization. The resulting precipitate was filtered off andwashed with n-hexane and dried. The resultant product (1) was usedfurther without any purification. Either of 4-hydroxy benzaldehyde(2a), vanillin (2b) or isovanillin (2c) (1 equivalent) was dissolved inacetone and potassium carbonate (2 equivalents) was added. Thencorresponding substituted acetamide (1) was mixed to the stirring solution.Finally, potassium iodide (1.5 equivalent) was added. The reactionmixture was refluxed for 8-10 h. After completion of reaction,the resultant mixture was concentrated and treated with water andextracted with ethyl acetate (3×20 mL). The organic layers werecombined and treated with brine and dried over sodium sulfate andconcentrated. The crude mixture was purified over silica gel (60-120)using petroleum ether: ethyl acetate (9:1).
With triethylamine; at 0 - 20℃; for 4h; General procedure: In a round bottom flask, primary or secondary amines (0.1 mol) and triethyl amine weredissolved in DCM and stirred at 0 C. 2-Chloroacetyl chloride (0.1 mol) was added to reaction mixture drop wise with continuous stirring on magnetic stirrer. After the addition,the ice bath was removed and the reaction mixture was stirred at room temperature for 4 h.The progress of the reaction was monitored by TLC using ethyl acetate: hexane (1:9) as asolvent system. After completion of the reaction, the reaction mixture was poured on crushedice and neutralised by adding acetic acid to it. The obtained solid intermediates of respectiveamines were filtered, dried and crystallised in ethanol.
With triethylamine; In dichloromethane; at 0 - 20℃; for 12h; General procedure: A stirred solution of aniline derivatives 1a-h (0.05 mol) in dichloromethane DCM (50 mL) was cooled to 0 C, and chloroacetyl chloride (0.06 mol) and triethylamine (0.06 mol) was added dropwise to the solution. The resulting mixture was warmed to room temperature and stirred overnight. The organic phase was diluted with DCM (50 mL) and washed with 0.5 M HCl (50 mL), then saturated with NaHCO3 and brine. The organic layer was collected and dried over anhydrous Na2SO4. Then, the solvent was removed under reduced pressure. The 2-chloro-N-phenylancetamide derivatives (5 mmol) obtained by recrystallization were refluxed with potassium iodide (7.5 mmol) in acetone (10 mL) for 6 h, and the solvent was evaporated in vacuo. Water (50 mL) was added to the reaction mixture, and the organic phase extracted with ethyl acetate was washed with brine, and dried over anhydrous Na2SO4. The solvent was evaporated, then recrystallized from ethyl acetate to obtain Compounds 2a-h [1-3]. Moxifloxacin (2 mmol) and TEA (4.4 mmol) were added to a stirred solution of 2-iodo-N-phenylancetamide derivatives 2a-h (2.2 mmol) in acetonitrile (10 mL). The mixture was heated under reflux for 12 h, then the solvent was removed under vacuum. The resulting solid was recrystallized using acetonitrile to afford eight 4a-h [4].
With triethylamine; In dichloromethane; at 0 - 20℃;Inert atmosphere; General procedure: The corresponding amine was dissolved in anhydrous dichloromethane at 0C, and then triethylamine (1.1 eq) was added under a nitrogen atmosphere. Chloroacetyl chloride (1.1 eq) diluted with anhydrous dichloromethane was slowly added to the reaction mixture in an ice bath. The reaction stirred at 0C for 30min, after which the reaction slowly warmed to room temperature overnight. TLC was used to monitor the reaction. After the reaction was complete, it was quenched with water and extracted with dichloromethane. The organic phase was retained and washed with an aqueous hydrochloric acid solution, an aqueous saturated sodium hydrogen carbonate solution, and brine three times. Anhydrous sodium sulfate was used to dry the organic phase, after which the solvent was removed under reduced pressure with a rotary evaporator to obtain crude product. The crude product was dissolved in ethyl acetate and recrystalized with petroleum ether to afford the final product. Compounds 5-14 were in 58-86% yield.

Reference: [1]Organic and Biomolecular Chemistry,2005,vol. 3,p. 2129 - 2139
[2]Bioorganic and Medicinal Chemistry,2014,vol. 22,p. 6885 - 6892
[3]Letters in drug design and discovery,2012,vol. 9,p. 402 - 408
[4]Patent: EP2322520,2011,A1 .Location in patent: Page/Page column 24
[5]Patent: JP5714152,2015,B2 .Location in patent: Page/Page column 29
[6]Journal of Medicinal Chemistry,2012,vol. 55,p. 6391 - 6402
[7]Bioorganic Chemistry,2021,vol. 114
[8]Bioorganic and Medicinal Chemistry Letters,2022,vol. 61
[9]Pharmaceutical Chemistry Journal,1981,vol. 15,p. 849 - 853
    Khimiko-Farmatsevticheskii Zhurnal,1981,vol. 15,p. 23 - 26
[10]Indian Journal of Chemistry - Section B Organic and Medicinal Chemistry,1986,vol. 25,p. 438 - 440
[11]Archiv der Pharmazie,2013,vol. 346,p. 793 - 804
[12]European Journal of Medicinal Chemistry,2020,vol. 198
[13]Bioorganic Chemistry,2022,vol. 119
[14]Bioorganic and Medicinal Chemistry,2004,vol. 12,p. 3471 - 3483
[15]Journal of the American Chemical Society,1919,vol. 41,p. 1457
[16]European Journal of Medicinal Chemistry,1985,vol. 20,p. 187 - 189
[17]Tetrahedron Letters,1998,vol. 39,p. 7459 - 7462
[18]Magnetic Resonance in Chemistry,2000,vol. 38,p. 384 - 385
[19]Bioorganic and Medicinal Chemistry,2006,vol. 14,p. 4820 - 4833
[20]Journal of Heterocyclic Chemistry,2007,vol. 44,p. 35 - 38
[21]Journal of Organic Chemistry,2009,vol. 74,p. 2846 - 2849
[22]Synthetic Communications,2009,vol. 39,p. 2723 - 2736
[23]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 2705 - 2708
[24]Bioorganic and Medicinal Chemistry Letters,2010,vol. 20,p. 4661 - 4664
[25]Chemical Biology and Drug Design,2011,vol. 78,p. 309 - 313
[26]Letters in Organic Chemistry,2011,vol. 8,p. 732 - 736
[27]Bioorganic and Medicinal Chemistry,2013,vol. 21,p. 4332 - 4341
[28]Chemical Biology and Drug Design,2014,vol. 84,p. 685 - 696
[29]Bioorganic and Medicinal Chemistry,2015,vol. 23,p. 6173 - 6184
[30]European Journal of Medicinal Chemistry,2016,vol. 107,p. 165 - 179
[31]Monatshefte fur Chemie,2016,vol. 147,p. 565 - 574
[32]Journal of Heterocyclic Chemistry,2016,vol. 53,p. 1595 - 1602
[33]Bioorganic and Medicinal Chemistry Letters,2016,vol. 26,p. 3679 - 3683
[34]European Journal of Medicinal Chemistry,2016,vol. 123,p. 814 - 821
[35]Medicinal Chemistry,2016,vol. 12,p. 631 - 639
[36]Archiv der Pharmazie,2016,vol. 349,p. 864 - 880
[37]Journal of Sulfur Chemistry,2017,vol. 38,p. 43 - 51
[38]MedChemComm,2017,vol. 8,p. 1421 - 1434
[39]Arkivoc,2017,vol. 2017,p. 316 - 325
[40]Chemical Papers,2018,vol. 72,p. 651 - 659
[41]Molecules,2018,vol. 23
[42]Bioorganic Chemistry,2018,vol. 80,p. 288 - 295
[43]Journal of Chemical Sciences,2018,vol. 130
[44]European Journal of Medicinal Chemistry,2019,vol. 165,p. 115 - 132
[45]European Journal of Pharmaceutical Sciences,2019,vol. 131,p. 177 - 194
[46]Journal of Heterocyclic Chemistry,2019,vol. 56,p. 1928 - 1938
[47]Journal of Heterocyclic Chemistry,2019,vol. 56,p. 2411 - 2418
[48]European Journal of Medicinal Chemistry,2019,vol. 182
[49]Synthetic Communications,2019
[50]Tetrahedron Letters,2020,vol. 61
[51]Bioorganic Chemistry,2020,vol. 100
[52]European Journal of Medicinal Chemistry,2020,vol. 196
[53]European Journal of Medicinal Chemistry,2020,vol. 208
[54]Journal of the Iranian Chemical Society,2021,vol. 18,p. 2035 - 2046
[55]Bioorganic and Medicinal Chemistry Letters,2021,vol. 38
[56]Journal of Medicinal Chemistry,2021,vol. 64,p. 6856 - 6876
[57]Journal of Medicinal Chemistry,2021,vol. 64,p. 6949 - 6971
[58]New Journal of Chemistry,2021,vol. 45,p. 13104 - 13118
[59]Bioorganic and Medicinal Chemistry,2021,vol. 43
[60]ChemMedChem,2022,vol. 17
  • 3
  • [ 17641-08-6 ]
  • [ 109-89-7 ]
  • [ 40517-65-5 ]
  • 4
  • [ 17641-08-6 ]
  • [ 31523-22-5 ]
  • N-(3-Methoxy-phenyl)-2-[N'-(5H-[1,2,4]triazino[5,6-b]indol-3-yl)-hydrazino]-acetamide [ No CAS ]
  • 5
  • [ 17641-08-6 ]
  • [ 64-17-5 ]
  • [ 77775-78-1 ]
  • [ 77775-79-2 ]
  • [ 588-16-9 ]
  • 6
  • [ 17641-08-6 ]
  • [ 17641-09-7 ]
YieldReaction ConditionsOperation in experiment
With potassium iodide; In acetone; for 6h;Reflux; General procedure: A stirred solution of aniline derivatives 1a-h (0.05 mol) in dichloromethane DCM (50 mL) was cooled to 0 C, and chloroacetyl chloride (0.06 mol) and triethylamine (0.06 mol) was added dropwise to the solution. The resulting mixture was warmed to room temperature and stirred overnight. The organic phase was diluted with DCM (50 mL) and washed with 0.5 M HCl (50 mL), then saturated with NaHCO3 and brine. The organic layer was collected and dried over anhydrous Na2SO4. Then, the solvent was removed under reduced pressure. The 2-chloro-N-phenylancetamide derivatives (5 mmol) obtained by recrystallization were refluxed with potassium iodide (7.5 mmol) in acetone (10 mL) for 6 h, and the solvent was evaporated in vacuo. Water (50 mL) was added to the reaction mixture, and the organic phase extracted with ethyl acetate was washed with brine, and dried over anhydrous Na2SO4. The solvent was evaporated, then recrystallized from ethyl acetate to obtain Compounds 2a-h [1-3]. Moxifloxacin (2 mmol) and TEA (4.4 mmol) were added to a stirred solution of 2-iodo-N-phenylancetamide derivatives 2a-h (2.2 mmol) in acetonitrile (10 mL). The mixture was heated under reflux for 12 h, then the solvent was removed under vacuum. The resulting solid was recrystallized using acetonitrile to afford eight 4a-h [4].
  • 7
  • [ 17641-08-6 ]
  • [ 77775-78-1 ]
  • [ 77775-79-2 ]
  • [ 588-16-9 ]
  • 9
  • [ 17641-08-6 ]
  • [ 147-93-3 ]
  • [ 97457-48-2 ]
  • 11
  • [ 17641-08-6 ]
  • [ 37893-08-6 ]
  • [ 132659-09-7 ]
  • 12
  • [ 17641-08-6 ]
  • [ 1904-60-5 ]
  • N-(3-Methoxy-phenyl)-2-(4-oxo-2-phenyl-4H-quinazolin-3-ylamino)-acetamide [ No CAS ]
  • 13
  • [ 17641-08-6 ]
  • [ 23269-70-7 ]
  • 2-[5-(4-Acetylamino-phenyl)-[1,3,4]oxadiazol-2-ylsulfanyl]-N-(3-methoxy-phenyl)-acetamide [ No CAS ]
  • 14
  • [ 17641-08-6 ]
  • [ 141-43-5 ]
  • 2-(2-Hydroxy-ethylamino)-N-(3-methoxy-phenyl)-acetamide [ No CAS ]
  • 15
  • [ 17641-08-6 ]
  • [ 873-55-2 ]
  • 2-benzenesulfonyl-<i>N</i>-(3-methoxy-phenyl)-acetamide [ No CAS ]
YieldReaction ConditionsOperation in experiment
63.8% With pyridine; In water; at 0℃; for 1h;Cooling with ice; General procedure: The 1.27g (10mmol, 1 . 0eq) 4-aminochlorobenzene into 1.6 ml pyridine with 20 ml of water in the mixed solution, under the condition in the ice bath, dripping therein 1.69g (15mmol, 1 . 5eq) chloro acetyl chloride. In 0 C reaction 1.0h, in to the system by adding 50 ml of water, filtering, filtering the solid obtained after drying 0.77g white powdery solid, can be without purification directly used for the next reaction, the yield is 37.7%
  • 17
  • [ 17641-08-6 ]
  • [ 74331-44-5 ]
  • <i>N</i>-(3-methoxy-phenyl)-2-(2-oxo-1,3-diphenyl-2,3-dihydro-1<i>H</i>-imidazol-4-ylsulfanyl)-acetamide [ No CAS ]
  • 18
  • [ 17641-08-6 ]
  • [ 74331-44-5 ]
  • 6-(3-methoxy-phenylamino)-1,3-diphenyl-1,3-dihydro-thieno[2,3-<i>d</i>]imidazol-2-one [ No CAS ]
  • 19
  • [ 17641-08-6 ]
  • 5-chloro benzoxazole 2-thiol potassium salt [ No CAS ]
  • 2-(5-chloro-benzooxazol-2-ylsulfanyl)-<i>N</i>-(3-methoxy-phenyl)-acetamide [ No CAS ]
  • 20
  • [ 17641-08-6 ]
  • [ 56278-50-3 ]
  • 5-amino-4-(2-benzothiazolyl)-2,3-dihydro-1-(3-methoxyphenyl)-2-pyrrolone [ No CAS ]
  • 21
  • [ 17641-08-6 ]
  • [ 610278-84-7 ]
  • 4-(5-amino-4-benzothiazol-2-yl-3-oxo-2,3-dihydro-pyrrol-1-yl)-benzoic acid (3-methoxy-phenylcarbamoyl)-methyl ester [ No CAS ]
  • 22
  • [ 17641-08-6 ]
  • [ 749216-03-3 ]
  • 3-{5-amino-4-[4-(4-chloro-phenyl)-thiazol-2-yl]-3-oxo-2,3-dihydro-pyrrol-1-yl}-benzoic acid (3-methoxy-phenylcarbamoyl)-methyl ester [ No CAS ]
Recommend Products
Same Skeleton Products

Technical Information

Historical Records
; ;